Best Practice & Research Clinical Haematology
Volume 23, Issue 1 , Pages 33-45 , March 2010

Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells

  • Rajendra N. Damle, Ph.D (Assistant Investigator, The Feinstein Institute for Medical Research)

      Affiliations

    • The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
    • Department of Medicine, NYU School of Medicine, NY, USA
    • ,
  • Carlo Calissano, M.D. (Postdoctoral Fellow, The Feinstein Institute for Medical Research)

      Affiliations

    • The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
    • ,
  • Nicholas Chiorazzi, M.D. (Investigator and Center Head, The Feinstein Institute for Medical Research)

      Affiliations

    • The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
    • Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA
    • Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 516 562 1090; Fax: +1 516 562 1011.

References 

  1. Pascual V, Liu YJ, Magalski A, et al. Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med. 1994;180(1):329–339
  2. Nolz JC, Tschumper RC, Pittner BT, et al. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia. 2005;19(6):1018–1024
  3. Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002;99(11):4087–4093
  4. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101(12):4944–4951
  5. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764–1775
  6. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–1847
  7. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001;98(9):2633–2639
  8. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood. 2003;101(4):1262–1269
  9. Deaglio S, Vaisitti T, Billington R, et al. CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood. 2007;109(12):5390–5398
  10. Chen L, Apgar J, Huynh L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood. 2005;105(5):2036–2041
  11. Sarfati M. CD23 and chronic lymphocytic leukemia. Blood Cells. 1993;19(3):591–596
  12. Hulkkonen J, Vilpo L, Hurme M, et al. Surface antigen expression in chronic lymphocytic leukemia: clustering analysis, interrelationships and effects of chromosomal abnormalities. Leukemia. 2002;16(2):178–185
  13. Vilpo J, Tobin G, Hulkkonen J, et al. Mitogen induced activation, proliferation and surface antigen expression patterns in unmutated and hypermutated chronic lymphocytic leukemia cells. Eur J Haematol. 2005;75(1):34–40
  14. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol. 2005;17(3):275–281
  15. Damle RN, Temburni S, Calissano C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood. 2007;110(9):3352–3359
  16. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115(3):755–764
  17. Calissano C, Damle RN, Hayes G, et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood. 2009;114(23):4832–4842
  18. Schmid C, Isaacson PG. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology. 1994;24(5):445–451
  19. Soma LA, Craig FE, Swerdlow SH. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol. 2006;37(2):152–159
  20. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 2001;97(9):2777–2783
  21. Schattner EJ, Mascarenhas J, Reyfman I, et al. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. Blood. 1998;91(8):2689–2697
  22. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood. 1995;85(12):3556–3565
  23. Trentin L, Zambello R, Sancetta R, et al. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res. 1997;57(21):4940–4947
  24. Patten PE, Buggins AG, Richards J, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood. 2008;111(10):5173–5181
  25. Serrano D, Monteiro J, Allen SL, et al. Clonal expansion within the CD4+CD57+ and CD8+CD57+T cell subsets in chronic lymphocytic leukemia. J Immunol. 1997;158(3):1482–1489
  26. Halper JP, Fu SM, Gottlieb AB, et al. Poor mixed lymphocyte reaction stimulatory capacity of leukemic B cells of chronic lymphocytic leukemia patients despite the presence of Ia antigens. J Clin Invest. 1979;64(5):1141–1148
  27. Chiorazzi N, Fu S, Montazeri G, et al. T cell helper defect in patients with chronic lymphocytic leukemia. J Immunol. 1979;1221087–1221090
  28. Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003;44(3):383–389
  29. Jak M, Mous R, Remmerswaal EBM, et al. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(5):788–801
  30. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427–2437
  31. Muzio M, Apollonio B, Scielzo C, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008;112(1):188–195
  32. Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood. 2002;100(10):3741–3748
  33. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997;100(12):3140–3148
  34. Wolowiec D, Ciszak L, Kosmaczewska A, et al. Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia. Haematologica. 2001;86(12):1296–1304
  35. Schrader C, Janssen D, Klapper W, et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer. 2005;93(8):939–945
  36. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257(2):231–237
  37. Brown DC, Gatter KC. Ki67 protein: the immaculate deception?. Histopathology. 2002;40(1):2–11
  38. Weng NP, Granger L, Hodes RJ. Telomere lengthening and telomerase activation during human B cell differentiation. Proc Natl Acad Sci U S A. 1997;94(20):10827–10832
  39. Trentin L, Ballon G, Ometto L, et al. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol. 1999;106(3):662–668
  40. Damle RN, Batliwalla FM, Ghiotto F, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood. 2004;103(2):375–382
  41. Lanham S, Hamblin T, Oscier D, et al. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101(3):1087–1093
  42. Cutrona G, Colombo M, Matis S, et-al. Clonal heterogeneity in CLL cells: response to surface IgM crosslinking is more efficient in CD38, ZAP-70 positive cells. Haematologica (in press).
  43. Efremov DG, Gobessi S, Longo PG. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun Rev. 2007;7(2):102–108
  44. Lyko F, Stach D, Brenner A, et al. Quantitative analysis of DNA methylation in chronic lymphocytic leukemia patients. Electrophoresis. 2004;25(10–11):1530–1535
  45. Yu MK, Bergonia H, Szabo A, et al. Progressive disease in chronic lymphocytic leukemia is correlated with the DNA methylation index. Leuk Res. 2007;31(6):773
  46. Kanduri M, Cahill N, Goransson H, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood. 2010;115(20):296–305
  47. Klein U, Goossens T, Fischer M, et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev. 1998;162261–162280
  48. Schroeder HW, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today. 1994;15(6):288–294
  49. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102(8):1515–1525
  50. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–1854
  51. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100(4):1410–1416
  52. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194(11):1639–1647
  53. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194(11):1625–1638
  54. Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 2000;12(6):676–684
  55. Wolowiec D, Deviller P, Simonin D, et al. Cdk1 is a marker of proliferation in human lymphoid cells. Int J Cancer. 1995;61(3):381–388
  56. Paul JT, Henson ES, Mai S, et al. Cyclin D expression in chronic lymphocytic leukemia. Leuk Lymphoma. 2005;46(9):1275–1285
  57. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804–815
  58. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Ann Rev Immunol. 2003;21:21841–21894
  59. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993;177(4):925–935
  60. Longo PG, Laurenti L, Gobessi S, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 2007;21(1):110–120
  61. Neese RA, Siler SQ, Cesar D, et al. Advances in the stable isotope-mass spectrometric measurement of DNA synthesis and cell proliferation. Anal Biochem. 2001;298(2):189–195
  62. Hellerstein MK, Neese RA. Mass isotopomer distribution analysis: a technique for measuring biosynthesis and turnover of polymers. Am J Physiol. 1992;263(5 Pt 1):E988–1001
  63. Rubini JR, Bond VP, Keller S, et al. DNA synthesis in circulating blood leukocytes labeled in vitro with H3-thymidine. J Lab Clin Med. 1961;58751–58762
  64. Zimmerman TS, Godwin HA, Perry S. Studies of leukocyte kinetics in chronic lymphocytic leukemia. Blood. 1968;31(3):277–291
  65. Theml H, Trepel G, Schick P, et al. Kinetics of lymphocytes in chronic lymphocytic leukemia: studies using continuous 3H-thymidine infusion in two patients. Blood. 1973;42623:
  66. Dormer P, Theml H, Lau B. Chronic lymphocytic leukemia: a proliferative or accumulative disorder?. Leuk Res. 1983;7(1):1–10
  67. Defoiche J, Debacq C, Asquith B, et al. Reduction of B cell turnover in chronic lymphocytic leukaemia. Br J Haematol. 2008;143(2):240–247
  68. van Gent R, Kater AP, Otto SA, et al. In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. Cancer Res. 2008;68(24):10137–10144
  69. Simonsson B, Nilsson K. 3H-thymidine uptake in chronic lymphocytic leukaemia cells. Scand J Haematol. 1980;24(2):169–173
  70. Montserrat E, Sanchez-Bisono J, Vinolas N, et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986;62(3):567–575
  71. Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer. 1987;60(11):2712–2716
  72. Winkelstein A, Craddock CG. Comparative response of normal human thymus and lymph node cells to phytohemagglutinin in culture. Blood. 1967;29(4 Suppl.):594–607
  73. Smit LA, Hallaert DY, Spijker R, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood. 2007;109(4):1660–1668
  74. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol. 2003;123(3):380–388
  75. Chilosi M, Pizzolo G, Caligaris-Cappio F, et al. Immunohistochemical demonstration of follicular dendritic cells in bone marrow involvement of B-cell chronic lymphocytic leukemia. Cancer. 1985;56(2):328–332
  76. Renno T, Attinger A, Locatelli S, et al. Cutting edge: apoptosis of superantigen-activated T cells occurs preferentially after a discrete number of cell divisions in vivo. J Immunol. 1999;162(11):6312–6315
  77. Mongini PKA, Inman JK, Han H, et al. Innate immunity and human B cell clonal expansion: effects on the recirculating B2 subpopulation. J Immunol. 2005;175(9):6143–6154
  78. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112(5):1923–1930
  79. Rassenti LZ, Hunynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893–901
  80. D’Arena G, Musto P, Nunziata G, et al. CD69 expression in B-cell chronic lymphocytic leukemia: a new prognostic marker?. Haematologica. 2001;86(9):995–996
  81. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24(28):4634–4641
  82. Shanafelt TD, Jelinek D, Tschumper R, et al. Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia. J Clin Oncol. 2006;24(19):3218–3219[Author reply pp. 3219–3220]

PII: S1521-6926(10)00009-5

doi: 10.1016/j.beha.2010.02.001

Best Practice & Research Clinical Haematology
Volume 23, Issue 1 , Pages 33-45 , March 2010

Article Tools

* Image Usage & Resolution